Key terms
About NKTX
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NKTX news
Mar 28
4:48pm ET
Nkarta director buys $20M in common stock
Mar 26
2:59pm ET
Promising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-Hearted
Mar 26
7:25am ET
TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)
Mar 25
10:05pm ET
Stifel Nicolaus Keeps Their Buy Rating on Nkarta (NKTX)
Mar 25
6:42am ET
Nkarta prices 21M shares at $10.00 in underwritten offering
Mar 25
6:22am ET
Nkarta’s NKX019 Shows Potential in Lymphoma Treatment
Mar 24
9:27pm ET
Nkarta’s Strategic Pivot to CAR-NK Therapies for Autoimmune Diseases Prompts Buy Rating
Mar 22
9:40am ET
Nkarta trading resumes
Mar 22
9:35am ET
Nkarta trading halted, volatility trading pause
Mar 22
7:10am ET
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Dianthus Therapeutics (DNTH) and Eli Lilly & Co (LLY)
Mar 22
6:48am ET
Nkarta price target lowered to $25 from $31 at Mizuho
Mar 22
6:45am ET
Nkarta’s Strategic Pivot to NKX019 Spurs Buy Rating Amid Strong Financials and Promising Trial Prospects
Mar 22
6:27am ET
Nkarta’s Strategic Focus and Financial Strength Underpin Buy Rating
Mar 22
6:26am ET
Buy Rating for Nkarta: Promising Future for NKX019 in Autoimmune Disease Treatment
Mar 22
4:43am ET
Nkarta downgraded to Outperform from Strong Buy at Raymond James
Mar 21
4:06pm ET
Nkarta: cash sufficient to fund current operating plan into 2026
Mar 21
4:05pm ET
Nkarta reports Q4 EPS (57c), consensus (59c)
Mar 21
2:35pm ET
Nkarta options imply 10.4% move in share price post-earnings
Mar 19
1:38am ET
Innovative NK-Cell Therapy: A Buy Rating for Nkarta’s Groundbreaking Approach to Autoimmune Diseases
Mar 04
9:13am ET
Nkarta price target raised to $31 from $9 at Mizuho
Feb 18
11:47pm ET
Leerink Partners Keeps Their Buy Rating on Nkarta (NKTX)
Jan 17
12:27am ET
3 Best Stocks to Buy Now, 1/17/2024, According to Top Analysts
Jan 11
1:34am ET
Nkarta’s Promising CAR-NK Cell Therapies: A ‘Buy’ Rating Reinforced by Robust Clinical Data and Strategic Advancements
Jan 11
1:31am ET
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Incyte (INCY) and Nkarta (NKTX)
Jan 09
7:36am ET
Stifel Nicolaus Sticks to Its Buy Rating for Nkarta (NKTX)
Jan 09
5:55am ET
Buy Rating for Nkarta’s Stock Backed by Promising CAR-NK Therapy Developments and Strategic Advantages
Jan 08
3:35pm ET
Buy Rating Reiterated for Nkarta Amid Promising Redosing Results and Broad Therapeutic Potential
No recent news articles are available for NKTX
No recent press releases are available for NKTX
NKTX Financials
Key terms
Ad Feedback
NKTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NKTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
